Kerstin Wimmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kerstin Wimmer has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Florian Fitzal
Department of General Surgery, Hanusch Hospital
6 shared publicationsGünther Steger
4 shared publicationsChristian F. Singer
Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
3 shared publicationsChristian Fesl
Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
3 shared publicationsChristoph Suppan
Department of Oncology, Medical University of Graz, Austria
3 shared publicationsDaniel Egle
Department of Gynecology, Medical University Innsbruck, Innsbruck, Austria
3 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1917346
Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort
Background: Neoadjuvant systemic therapy (NST) has become a cornerstone in the management of aggressive early breast cancer (BC) subtypes, including triple-negative (eTNBC) and HER2-positive disease. Immune checkpoint inhibition with pembrolizumab represents an active immunotherapeutic approach, whereas dual HER2 blockade with trastuzumab and pertuzumab constitutes passive immunotherapy in early HER2-positive BC. Although both strategies demonstrate substantial antitumor efficacy, real-world data directly comparing their surgical safety profiles are limited. Materials and methods: This retrospective single-center cohort study included 99 patients with early BC treated with NST between 2014 and 2025. A total of 33 patients with TNBC received pembrolizumab-based therapy according to the KEYNOTE-522 regimen, whereas 66 patients with HER2-positive disease received chemotherapy combined with trastuzumab and pertuzumab. Surgical adverse events within 30 days postoperatively were assessed using the Clavien–Dindo classification and the Comprehensive Complication Index (CCI). Complication rates and severity were compared between groups. Results: The overall postoperative complication rate was 25.3%, with no significant difference between TNBC and HER2-positive cohorts (27.3% vs. 24.2%, p = 0.744). Most complications were minor (Clavien–Dindo ≤II), and rates of major complications (≥IIIa) did not differ between groups ( p = 0.706). Mean CCI scores were comparable (22.1 vs. 24.4; p = 0.630). Seroma formation was the most frequent adverse event in both cohorts. In an exploratory multivariable logistic regression analysis, treatment group was not independently associated with postoperative complications. Pathological complete response rates were 63.6% in TNBC and 45.5% in HER2-positive patients. No clinically relevant delays in adjuvant radiotherapy occurred. Conclusion: No statistically significant differences in postoperative morbidity were observed between treatment groups. These findings support the feasibility of integrating both neoadjuvant treatment strategies into routine surgical practice; however, confirmation in larger prospective studies is warranted.
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1917346
Open AccessNeoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort
Background: Neoadjuvant systemic therapy (NST) has become a cornerstone in the management of aggressive early breast cancer (BC) subtypes, including triple-negative (eTNBC) and HER2-positive disease. Immune checkpoint inhibition with pembrolizumab represents an active immunotherapeutic approach, whereas dual HER2 blockade with trastuzumab and pertuzumab constitutes passive immunotherapy in early HER2-positive BC. Although both strategies demonstrate substantial antitumor efficacy, real-world data directly comparing their surgical safety profiles are limited. Materials and methods: This retrospective single-center cohort study included 99 patients with early BC treated with NST between 2014 and 2025. A total of 33 patients with TNBC received pembrolizumab-based therapy according to the KEYNOTE-522 regimen, whereas 66 patients with HER2-positive disease received chemotherapy combined with trastuzumab and pertuzumab. Surgical adverse events within 30 days postoperatively were assessed using the Clavien–Dindo classification and the Comprehensive Complication Index (CCI). Complication rates and severity were compared between groups. Results: The overall postoperative complication rate was 25.3%, with no significant difference between TNBC and HER2-positive cohorts (27.3% vs. 24.2%, p = 0.744). Most complications were minor (Clavien–Dindo ≤II), and rates of major complications (≥IIIa) did not differ between groups ( p = 0.706). Mean CCI scores were comparable (22.1 vs. 24.4; p = 0.630). Seroma formation was the most frequent adverse event in both cohorts. In an exploratory multivariable logistic regression analysis, treatment group was not independently associated with postoperative complications. Pathological complete response rates were 63.6% in TNBC and 45.5% in HER2-positive patients. No clinically relevant delays in adjuvant radiotherapy occurred. Conclusion: No statistically significant differences in postoperative morbidity were observed between treatment groups. These findings support the feasibility of integrating both neoadjuvant treatment strategies into routine surgical practice; however, confirmation in larger prospective studies is warranted.
- Open Access
Characterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer Cohort
Purpose: Male breast cancer (maleBC) is an orphan disease. Aside from age, risk factors include genetic mutations and conditions like Klinefelter syndrome or other reasons of hypogonadism. Treatment is based on standards in women, but biological differences may exist, with maleBC exhibiting higher rates of hormone-receptor expression. Limiting data exists regarding the rate of low/ultralow HER2 expression, a predictive biomarker for the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in HER2-negative disease in women. Materials and Methods: We conducted a retrospective single-center analysis of clinicopathological features of maleBC at a tertiary cancer center. We identified a cohort of 57 maleBC patients, described demographic, pathological, prognostic and surgical and systemic treatment data and evaluated frequencies of low and ultralow HER2 expression. Results: The mean age was 64.3 (SE ± 1.79) years; 94.7% (n = 54) of patients presented with early/nonmetastatic breast cancer and 40.7% (22 of 54) of patients exhibited nodal involvement. Most patients (92.6%, 50 of 54 patients) had luminal disease and approximately one third of patients received chemotherapy. Endocrine therapy was administered in 87.7% (n = 50/57) of cases. For 52 of the patients included, full receptor status data including HER2 IHC scoring and/or histological specimens were available. IHC slides of tumor specimens from 24 patients with either historically reported “HER2 negative” or “HER2 0” expression were available for reassessment; 79.2% (n = 19 of 24) of these tumors exhibited either HER2-low or -ultralow expression. In the whole cohort, rates of HER2-low and -ultralow expression were 75.0% (39 of 52) and 5.8% (3 of 52 patients), respectively. The median follow-up was 7 years. Six deaths occurred in the total population (n = 57). The median event-free survival (EFS) was 8.39 years (95% CI 7.36–11.35). No statistically significant associations were observed between HER2 expression categories and clinicopathological variables including grade, ER status, nodal status, genetic variant status, age, Ki67 index, or overall survival events. Conclusions: In this cohort of maleBC patients, high rates of combined HER2-low and -ultralow expression were observed upon reassessment of tumors with historically negative HER2 status, shedding light on potential ADC eligibility in male breast cancer.
Open AccessCharacterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer Cohort
Purpose: Male breast cancer (maleBC) is an orphan disease. Aside from age, risk factors include genetic mutations and conditions like Klinefelter syndrome or other reasons of hypogonadism. Treatment is based on standards in women, but biological differences may exist, with maleBC exhibiting higher rates of hormone-receptor expression. Limiting data exists regarding the rate of low/ultralow HER2 expression, a predictive biomarker for the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in HER2-negative disease in women. Materials and Methods: We conducted a retrospective single-center analysis of clinicopathological features of maleBC at a tertiary cancer center. We identified a cohort of 57 maleBC patients, described demographic, pathological, prognostic and surgical and systemic treatment data and evaluated frequencies of low and ultralow HER2 expression. Results: The mean age was 64.3 (SE ± 1.79) years; 94.7% (n = 54) of patients presented with early/nonmetastatic breast cancer and 40.7% (22 of 54) of patients exhibited nodal involvement. Most patients (92.6%, 50 of 54 patients) had luminal disease and approximately one third of patients received chemotherapy. Endocrine therapy was administered in 87.7% (n = 50/57) of cases. For 52 of the patients included, full receptor status data including HER2 IHC scoring and/or histological specimens were available. IHC slides of tumor specimens from 24 patients with either historically reported “HER2 negative” or “HER2 0” expression were available for reassessment; 79.2% (n = 19 of 24) of these tumors exhibited either HER2-low or -ultralow expression. In the whole cohort, rates of HER2-low and -ultralow expression were 75.0% (39 of 52) and 5.8% (3 of 52 patients), respectively. The median follow-up was 7 years. Six deaths occurred in the total population (n = 57). The median event-free survival (EFS) was 8.39 years (95% CI 7.36–11.35). No statistically significant associations were observed between HER2 expression categories and clinicopathological variables including grade, ER status, nodal status, genetic variant status, age, Ki67 index, or overall survival events. Conclusions: In this cohort of maleBC patients, high rates of combined HER2-low and -ultralow expression were observed upon reassessment of tumors with historically negative HER2 status, shedding light on potential ADC eligibility in male breast cancer.
- Open Access
- 1 April 2026
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 19 (2) , 80-83
Current surgical standards in the management of the axilla
Summary: Axillary surgery in breast cancer has undergone a profound transformation in recent decades. While axillary lymph node dissection (ALND) was the unquestioned standard until the 1990s [1], associated morbidity including lymphedema rates as high as 25% in the affected arm [2], led to the widespread adoption of sentinel lymph node biopsy (SLNB). Recent data now suggest that even SLNB may be safely omitted in selected low-risk patients. This article reviews the evolution of axillary management, summarizes pivotal evidence from the INSEMA, SOUND and BOOG 13-08 trials, and discusses the clinical implications, limitations, and future directions of this ongoing de-escalation process.
- 1 April 2026
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 19 (2) , 80-83
Open AccessCurrent surgical standards in the management of the axilla
Summary: Axillary surgery in breast cancer has undergone a profound transformation in recent decades. While axillary lymph node dissection (ALND) was the unquestioned standard until the 1990s [1], associated morbidity including lymphedema rates as high as 25% in the affected arm [2], led to the widespread adoption of sentinel lymph node biopsy (SLNB). Recent data now suggest that even SLNB may be safely omitted in selected low-risk patients. This article reviews the evolution of axillary management, summarizes pivotal evidence from the INSEMA, SOUND and BOOG 13-08 trials, and discusses the clinical implications, limitations, and future directions of this ongoing de-escalation process.
- Open Access
- 3 October 2025
- Published by S. Karger AG in Breast Care
- Vol. 21 (3) , 212-223
Surgical Outcome Parameters in Breast Cancer: A Survey Comparing Oncoplastic and Non-Oncoplastic Surgeons as well as Certified with Non-Certified Breast Health Centers
Introduction: Breast cancer surgery has evolved over the past few decades, with an increase in the number of oncoplastic surgeons and certified breast centers worldwide. However, it remains unclear whether this has led to an improvement in the overall quality of care. Oncoplastic surgery combines oncologic tumor resection with plastic-reconstructive surgical techniques, performed either by two surgeons (two-team approach) or by a single oncoplastic surgeon (one-team approach), depending on the respective training system. The one-team approach offers organizational advantages but raises concerns regarding oncological outcomes. This study compares surgical outcome parameters between oncoplastic and non-oncoplastic surgeons and between certified and non-certified breast health centers. Methods: A two-part questionnaire with 9 general and 16 specific questions regarding surgical treatment between 2018 and 2022 was developed to assess parameters such as the rate of R1 resections, re-operations due to complications, immediate reconstructions and the number of mastectomies. A total of 173 members of four major international professional societies, representing more than 1,000 individuals in total, responded to the questionnaire. Results: A total of 125 individuals were included in the analysis. Most respondents specialized in general surgery, and most performed oncoplastic procedures in certified breast centers. The majority of respondents reported a need for further training. Oncoplastic surgeons had the highest caseload. Non-oncoplastic surgeons had the lowest rates of mastectomy, while surgeons specializing exclusively in breast surgery had the highest rates of immediate breast reconstruction. R1 resection rates varied between surgeons and centers, and higher complication rates were observed in non-certified centers. Conclusion: Our study showed that oncoplastic surgeons performed more oncoplastic procedures and immediate reconstruction after mastectomy. The use of intraoperative frozen section analysis and advances in training play a crucial role in minimizing complications or re-resection.
- 3 October 2025
- Published by S. Karger AG in Breast Care
- Vol. 21 (3) , 212-223
Open AccessSurgical Outcome Parameters in Breast Cancer: A Survey Comparing Oncoplastic and Non-Oncoplastic Surgeons as well as Certified with Non-Certified Breast Health Centers
Introduction: Breast cancer surgery has evolved over the past few decades, with an increase in the number of oncoplastic surgeons and certified breast centers worldwide. However, it remains unclear whether this has led to an improvement in the overall quality of care. Oncoplastic surgery combines oncologic tumor resection with plastic-reconstructive surgical techniques, performed either by two surgeons (two-team approach) or by a single oncoplastic surgeon (one-team approach), depending on the respective training system. The one-team approach offers organizational advantages but raises concerns regarding oncological outcomes. This study compares surgical outcome parameters between oncoplastic and non-oncoplastic surgeons and between certified and non-certified breast health centers. Methods: A two-part questionnaire with 9 general and 16 specific questions regarding surgical treatment between 2018 and 2022 was developed to assess parameters such as the rate of R1 resections, re-operations due to complications, immediate reconstructions and the number of mastectomies. A total of 173 members of four major international professional societies, representing more than 1,000 individuals in total, responded to the questionnaire. Results: A total of 125 individuals were included in the analysis. Most respondents specialized in general surgery, and most performed oncoplastic procedures in certified breast centers. The majority of respondents reported a need for further training. Oncoplastic surgeons had the highest caseload. Non-oncoplastic surgeons had the lowest rates of mastectomy, while surgeons specializing exclusively in breast surgery had the highest rates of immediate breast reconstruction. R1 resection rates varied between surgeons and centers, and higher complication rates were observed in non-certified centers. Conclusion: Our study showed that oncoplastic surgeons performed more oncoplastic procedures and immediate reconstruction after mastectomy. The use of intraoperative frozen section analysis and advances in training play a crucial role in minimizing complications or re-resection.
- Open Access
- 14 April 2025
- Published by S. Karger AG in Breast Care
- Vol. 20 (4) , 280-287
Risk Assessment Using Gene Expression Profiling Correlates with Clinical Prognosis Estimation in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer
Background: Gene expression profiles (GEPs) are recommended for tailoring adjuvant treatment in patients with hormone receptor (HR)-positive/HER2-negative breast cancer (BC) with intermediate clinical and pathological risk. This single-center retrospective study aimed at evaluating the clinical relevance of the additive information provided by GEPs in clinical routine at a tertiary care center. Methods: From 03/2010 to 07/2019, GEPs by either MammaPrint (MP) or PAM50 of HR-positive/HER2-negative early-stage BC were retrospectively included in the study. Pseudonymized data were processed for statistical analysis. Correlations between clinical and molecular risk markers were calculated. Survival was estimated using the Kaplan-Meier method. Results: Clinical and molecular risk data were available for 213 patients; complete follow-up data were available for 189 patients. According to GEPs by either MP (n = 69) or PAM50 (n = 144), 67 patients (31.5%) had low, 58 (27.2%) intermediate only in PAM50, and 88 (41.3%) high-risk BC. The MP group showed a higher rate of molecular low-risk tumors, while tumors analyzed by PAM50 were more frequent in a molecular high-risk situation. A significant correlation of proliferation rate and grading with the molecular risk score was observed (p < 0.001 each). Adjuvant chemotherapy was recommended in 87.5% of molecular high-risk tumors but administered in 64.8% only. Interestingly, a worse DFS was detected in the molecular low-risk group compared to the high-risk group (p = 0.55). It may be assumed that this is associated with an advanced tumor stage in these patients. Conclusion: In HR-positive/HER2-negative BC, proliferation rate as well as tumor grade correlated significantly with risk assessment by GEPs. Despite a high-risk result, chemotherapy is often omitted due to patient-specific factors such as age, comorbidities, or patients’ preference. On the other hand, survival with genomic low-risk tumors is likely to be compromised to more advanced stage, questioning the clinical validity of GEPs in these cases.
- 14 April 2025
- Published by S. Karger AG in Breast Care
- Vol. 20 (4) , 280-287
Open AccessRisk Assessment Using Gene Expression Profiling Correlates with Clinical Prognosis Estimation in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer
Background: Gene expression profiles (GEPs) are recommended for tailoring adjuvant treatment in patients with hormone receptor (HR)-positive/HER2-negative breast cancer (BC) with intermediate clinical and pathological risk. This single-center retrospective study aimed at evaluating the clinical relevance of the additive information provided by GEPs in clinical routine at a tertiary care center. Methods: From 03/2010 to 07/2019, GEPs by either MammaPrint (MP) or PAM50 of HR-positive/HER2-negative early-stage BC were retrospectively included in the study. Pseudonymized data were processed for statistical analysis. Correlations between clinical and molecular risk markers were calculated. Survival was estimated using the Kaplan-Meier method. Results: Clinical and molecular risk data were available for 213 patients; complete follow-up data were available for 189 patients. According to GEPs by either MP (n = 69) or PAM50 (n = 144), 67 patients (31.5%) had low, 58 (27.2%) intermediate only in PAM50, and 88 (41.3%) high-risk BC. The MP group showed a higher rate of molecular low-risk tumors, while tumors analyzed by PAM50 were more frequent in a molecular high-risk situation. A significant correlation of proliferation rate and grading with the molecular risk score was observed (p < 0.001 each). Adjuvant chemotherapy was recommended in 87.5% of molecular high-risk tumors but administered in 64.8% only. Interestingly, a worse DFS was detected in the molecular low-risk group compared to the high-risk group (p = 0.55). It may be assumed that this is associated with an advanced tumor stage in these patients. Conclusion: In HR-positive/HER2-negative BC, proliferation rate as well as tumor grade correlated significantly with risk assessment by GEPs. Despite a high-risk result, chemotherapy is often omitted due to patient-specific factors such as age, comorbidities, or patients’ preference. On the other hand, survival with genomic low-risk tumors is likely to be compromised to more advanced stage, questioning the clinical validity of GEPs in these cases.
- Open Access
- 19 February 2025
- Published by Elsevier in The Breast
- Vol. 80, 104415
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
- 19 February 2025
- Published by Elsevier in The Breast
- Vol. 80, 104415
Open AccessValidation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
- Open Access
- 5 May 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 206 (2) , 441
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
- 5 May 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 206 (2) , 441
Open AccessCorrection: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
- Open Access
- 25 January 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (2) , 227-239
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Purpose: The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of endocrine therapy (ET). Apart from evaluating the prognostic value and calibration accuracy of CTS5, the aim of this study is to clarify if this score is able to identify patients at higher risk for LDR who will benefit from extended ET. Methods: Prognostic power, calibration, and predictive value of the CTS5 was tested in patients of the prospective ABCSG-06 and -06a trials (n = 1254 and 860 patients, respectively). Time to LDR was analyzed with Cox regression models. Results: Higher rates of LDR in the years five to ten were observed in high- and intermediate-risk patients compared to low-risk patients (HR 4.02, 95%CI 2.26–7.15, p < 0.001 and HR 1.93, 95%CI 1.05–3.56, p = 0.035). An increasing continuous CTS5 was associated with increasing LDR risk (HR 2.23, 95% CI 1.74–2.85, p < 0.001). Miscalibration of CTS5 in high-risk patients could be observed. Although not reaching significance, high-risk patients benefitted the most from prolonged ET with an absolute reduction of the estimated 5-year LDR of − 6.1% (95%CI − 14.4 to 2.3). Conclusion: The CTS5 is a reliable prognostic tool that is well calibrated in the lower and intermediate risk groups with a substantial difference of expected versus observed LDR rates in high-risk patients. While a numerical trend in favoring prolonged ET for patients with a higher CTS5 was found, a significantly predictive value for the score could not be confirmed. Clinical trial registration: ABCSG-06 trial (NCT00309491), ABCSG-06A7 1033AU/0001 (NCT00300508).
- 25 January 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (2) , 227-239
Open AccessIs the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Purpose: The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of endocrine therapy (ET). Apart from evaluating the prognostic value and calibration accuracy of CTS5, the aim of this study is to clarify if this score is able to identify patients at higher risk for LDR who will benefit from extended ET. Methods: Prognostic power, calibration, and predictive value of the CTS5 was tested in patients of the prospective ABCSG-06 and -06a trials (n = 1254 and 860 patients, respectively). Time to LDR was analyzed with Cox regression models. Results: Higher rates of LDR in the years five to ten were observed in high- and intermediate-risk patients compared to low-risk patients (HR 4.02, 95%CI 2.26–7.15, p < 0.001 and HR 1.93, 95%CI 1.05–3.56, p = 0.035). An increasing continuous CTS5 was associated with increasing LDR risk (HR 2.23, 95% CI 1.74–2.85, p < 0.001). Miscalibration of CTS5 in high-risk patients could be observed. Although not reaching significance, high-risk patients benefitted the most from prolonged ET with an absolute reduction of the estimated 5-year LDR of − 6.1% (95%CI − 14.4 to 2.3). Conclusion: The CTS5 is a reliable prognostic tool that is well calibrated in the lower and intermediate risk groups with a substantial difference of expected versus observed LDR rates in high-risk patients. While a numerical trend in favoring prolonged ET for patients with a higher CTS5 was found, a significantly predictive value for the score could not be confirmed. Clinical trial registration: ABCSG-06 trial (NCT00309491), ABCSG-06A7 1033AU/0001 (NCT00300508).
- Open Access
- 14 November 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-14
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
Background: Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 inhibition. However, the expected stimulatory effect on lymphocytes may depend on the chemotherapy backbone. Therefore, we separately compared the immunomodulatory effects of EC and D in the setting of a randomized clinical trial. Methods: Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tumor-infiltrating lymphocytes, circulating lymphocytes and 14 soluble immune mediators were determined at baseline and at drug change. Furthermore, six BC cell lines were treated with E, C or D and co-cultured with immune cells. Results: Initial treatment with four cycles of EC reduced circulating B and T cells by 94% and 45%, respectively. In contrast, no comparable effects on lymphocytes were observed in patients treated with initial four cycles of D. Most immune mediators decreased under EC whereas D-treatment resulted in elevated levels of CXCL10, urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR). Accordingly, only the exposure of BC cell lines to D induced similar increases as compared to E. While treatment of BC cells with E was associated with cell shrinkage and apoptosis, D induced cell swelling and accumulation of cells in G2 phase. Conclusion: The deleterious effect of EC on lymphocytes indicates strong immunosuppressive properties of this combination therapy. D, in contrast, has no effect on lymphocytes, but triggers the secretion of stimulatory proteins in vivo and in vitro, indicating a supportive effect on the immune system. Underlying differences in the induced cell death might be causal. These divergent immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel should be considered when planning future combinations with immunotherapies in breast cancer.
- 14 November 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-14
Open AccessDifferential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
Background: Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 inhibition. However, the expected stimulatory effect on lymphocytes may depend on the chemotherapy backbone. Therefore, we separately compared the immunomodulatory effects of EC and D in the setting of a randomized clinical trial. Methods: Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tumor-infiltrating lymphocytes, circulating lymphocytes and 14 soluble immune mediators were determined at baseline and at drug change. Furthermore, six BC cell lines were treated with E, C or D and co-cultured with immune cells. Results: Initial treatment with four cycles of EC reduced circulating B and T cells by 94% and 45%, respectively. In contrast, no comparable effects on lymphocytes were observed in patients treated with initial four cycles of D. Most immune mediators decreased under EC whereas D-treatment resulted in elevated levels of CXCL10, urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR). Accordingly, only the exposure of BC cell lines to D induced similar increases as compared to E. While treatment of BC cells with E was associated with cell shrinkage and apoptosis, D induced cell swelling and accumulation of cells in G2 phase. Conclusion: The deleterious effect of EC on lymphocytes indicates strong immunosuppressive properties of this combination therapy. D, in contrast, has no effect on lymphocytes, but triggers the secretion of stimulatory proteins in vivo and in vitro, indicating a supportive effect on the immune system. Underlying differences in the induced cell death might be causal. These divergent immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel should be considered when planning future combinations with immunotherapies in breast cancer.
- Open Access
- 24 May 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (7) , e1003-e1011
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study
- 24 May 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (7) , e1003-e1011
Open AccessEffects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study